{"id":351066,"date":"2025-08-25T20:21:20","date_gmt":"2025-08-25T20:21:20","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-corbus-pharmaceuticals-holdings\/"},"modified":"2025-08-25T20:21:20","modified_gmt":"2025-08-25T20:21:20","slug":"how-to-buy-corbus-pharmaceuticals-holdings","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/","title":{"rendered":"Corbus Pharmaceuticals Holdings, Inc. (CRBP) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Corbus Pharmaceuticals Holdings, Inc. (CRBP) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334009,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-351066","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Corbus Pharmaceuticals Holdings, Inc. (CRBP) Hisseleri Nas\u0131l Al\u0131n\u0131r - Corbus Pharmaceuticals Holdings, Inc. (CRBP) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Corbus Pharmaceuticals Holdings, Inc. (CRBP) Hisseleri Nas\u0131l Al\u0131n\u0131r - Corbus Pharmaceuticals Holdings, Inc. (CRBP) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Corbus Pharmaceuticals Holdings, Inc. (CRBP) hisseleri nas\u0131l al\u0131n\u0131r, mevcut fiyat trendleri nas\u0131l analiz edilir ve bu yenilik\u00e7i biyoteknoloji \u015firketindeki yat\u0131r\u0131m f\u0131rsatlar\u0131 nas\u0131l anla\u015f\u0131l\u0131r \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Corbus Pharmaceuticals Holdings, Inc. (CRBP) hisseleri nas\u0131l al\u0131n\u0131r, mevcut fiyat trendleri nas\u0131l analiz edilir ve bu yenilik\u00e7i biyoteknoloji \u015firketindeki yat\u0131r\u0131m f\u0131rsatlar\u0131 nas\u0131l anla\u015f\u0131l\u0131r \u00f6\u011frenin."},"intro":"\u0130leri teknoloji biyoteknoloji yeniliklerine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Corbus Pharmaceuticals (CRBP), \u00e7\u0131\u011f\u0131r a\u00e7an t\u0131bbi ke\u015fiflerin ola\u011fan\u00fcst\u00fc yat\u0131r\u0131m f\u0131rsatlar\u0131 yaratabilece\u011fi klinik a\u015famadaki ila\u00e7 geli\u015ftirme d\u00fcnyas\u0131n\u0131n heyecan verici y\u00fcz\u00fcn\u00fc temsil ediyor. Bu \u015firket, sa\u011fl\u0131k hizmetlerinin en umut verici iki alan\u0131 olan onkoloji ve metabolik hastal\u0131k ara\u015ft\u0131rmalar\u0131n\u0131n kesi\u015fim noktas\u0131nda yer al\u0131yor. Bu potansiyel t\u0131bbi devrimin bir par\u00e7as\u0131na nas\u0131l sahip olabilece\u011finizi ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"\u0130leri teknoloji biyoteknoloji yeniliklerine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Corbus Pharmaceuticals (CRBP), \u00e7\u0131\u011f\u0131r a\u00e7an t\u0131bbi ke\u015fiflerin ola\u011fan\u00fcst\u00fc yat\u0131r\u0131m f\u0131rsatlar\u0131 yaratabilece\u011fi klinik a\u015famadaki ila\u00e7 geli\u015ftirme d\u00fcnyas\u0131n\u0131n heyecan verici y\u00fcz\u00fcn\u00fc temsil ediyor. Bu \u015firket, sa\u011fl\u0131k hizmetlerinin en umut verici iki alan\u0131 olan onkoloji ve metabolik hastal\u0131k ara\u015ft\u0131rmalar\u0131n\u0131n kesi\u015fim noktas\u0131nda yer al\u0131yor. Bu potansiyel t\u0131bbi devrimin bir par\u00e7as\u0131na nas\u0131l sahip olabilece\u011finizi ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 CRBP Hisse Analizi: Mevcut Fiyat ve Piyasa Konumu<\/h2> <p>25 A\u011fustos 2025 itibar\u0131yla Corbus Pharmaceuticals Holdings, Inc. (CRBP) <strong>9,22 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor\u2014bu volatil biyoteknoloji hissesi i\u00e7in kritik bir d\u00f6neme\u00e7. Hisse senedi bir ini\u015f \u00e7\u0131k\u0131\u015f treni ya\u015fad\u0131, ancak mevcut seviyeler bilgili yat\u0131r\u0131mc\u0131lar i\u00e7in ilgi \u00e7ekici f\u0131rsatlar sunuyor.<\/p> <p><strong>Takviminize not edin: Kas\u0131m 2025 kesinlikle kritik!<\/strong> CRBP'nin bir sonraki kazan\u00e7 raporunu a\u00e7\u0131klamas\u0131 bekleniyor ve tarihsel olarak bu anlar biyoteknoloji hisselerinde b\u00fcy\u00fck fiyat hareketleri yarat\u0131yor.<\/p> <h3>Klinik Deneme Sonu\u00e7lar\u0131 CRBP Hissesini Nas\u0131l Hareket Ettirir<\/h3> <p>Biyoteknoloji sekt\u00f6r\u00fc klinik deneme sonu\u00e7lar\u0131na ba\u011fl\u0131d\u0131r. CRBP i\u00e7in desen a\u00e7\u0131k: olumlu veriler patlay\u0131c\u0131 y\u00fckseli\u015f yarat\u0131rken, hayal k\u0131r\u0131kl\u0131\u011f\u0131 yaratan sonu\u00e7lar \u015fiddetli sat\u0131\u015flara yol a\u00e7ar. \u015eirketin son finansal istikrar\u0131\u2014<a href=\"https:\/\/ir.corbuspharma.com\/news-events\/press-releases\/detail\/447\/corbus-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\">2025 2. \u00e7eyrek itibar\u0131yla 116,6 milyon $ nakit pozisyonu<\/a>\u2014kritik veri a\u00e7\u0131klamalar\u0131nda \u00f6nemli bir destek sa\u011fl\u0131yor.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udd04 6 Ayl\u0131k Fiyat Yolculu\u011fu: Umutsuzluktan Umuda<\/h2> <p>CRBP son alt\u0131 ayda a\u015f\u0131r\u0131 volatilite ya\u015fad\u0131 ve biyoteknoloji yat\u0131r\u0131m\u0131n\u0131n y\u00fcksek risk, y\u00fcksek \u00f6d\u00fcl do\u011fas\u0131n\u0131 m\u00fckemmel \u015fekilde g\u00f6sterdi:<\/p> <table> <thead> <tr><th>Ay<\/th><th>Fiyat Aral\u0131\u011f\u0131<\/th><th>Ana Kataliz\u00f6r<\/th><\/tr> <\/thead> <tbody> <tr><td>Mart 2025<\/td><td>4,50 $-6,20 $<\/td><td>Piyasa belirsizli\u011fi, sekt\u00f6r rotasyonu<\/td><\/tr> <tr><td>Nisan 2025<\/td><td>5,80 $-7,40 $<\/td><td>Erken CRB-701 veri iyimserli\u011fi<\/td><\/tr> <tr><td>May\u0131s 2025<\/td><td>6,90 $-8,70 $<\/td><td>RBC Capital Markets sunum heyecan\u0131<\/td><\/tr> <tr><td>Haziran 2025<\/td><td>7,20 $-9,10 $<\/td><td>CRB-913 Faz 1 ba\u015flat\u0131lmas\u0131<\/td><\/tr> <tr><td>Temmuz 2025<\/td><td>8,50 $-10,80 $<\/td><td>2. \u00e7eyrek kazan\u00e7lar\u0131 beklentilerin \u00fczerinde<\/td><\/tr> <tr><td>A\u011fustos 2025<\/td><td>8,80 $-11,20 $<\/td><td>ESMO 2025 beklentisi art\u0131yor<\/td><\/tr> <\/tbody> <\/table> <p><strong>Genel Trend<\/strong>: Mart diplerinden %104 toparlanma, ba\u015far\u0131l\u0131 biyoteknoloji d\u00f6n\u00fc\u015flerinde inan\u0131lmaz toparlanma potansiyelini g\u00f6steriyor.<\/p> <p>Hissenin \u015fiddetli dalgalanmalar\u0131 klinik deneme sonu\u00e7lar\u0131n\u0131n ikili do\u011fas\u0131n\u0131 yans\u0131t\u0131yor\u2014her veri a\u00e7\u0131klamas\u0131 \u015firketi yapabilecek veya bozabilecek bir olayd\u0131r.<\/p> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut klinik ilerleme ve analist projeksiyonlar\u0131na dayanarak, gelecekte neler olabilece\u011fine dair \u00f6ng\u00f6r\u00fcler:<\/p> <p><strong>2025 Y\u0131l Sonu<\/strong>: 18-25 $ aral\u0131\u011f\u0131 (%95-171 y\u00fckseli\u015f)<\/p> <ul> <li>Kataliz\u00f6rler: ESMO veri a\u00e7\u0131klamas\u0131, CRB-913 Faz 1 tamamlanmas\u0131<\/li> <li><strong>Karar<\/strong>: Risk tolerans\u0131 y\u00fcksek yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00dc\u00c7L\u00dc ALIM<\/li> <\/ul> <p><strong>2026 Projeksiyonu<\/strong>: 30-45 $ aral\u0131\u011f\u0131<\/p> <ul> <li>FDA H\u0131zland\u0131r\u0131lm\u0131\u015f Onay tasar\u0131lar\u0131 geni\u015fleyebilir<\/li> <li>Ortakl\u0131k f\u0131rsatlar\u0131 \u015fekilleniyor<\/li> <\/ul> <p><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 60-85 $ aral\u0131\u011f\u0131<\/p> <ul> <li>Muhtemel ilk ticari \u00fcr\u00fcn lansmanlar\u0131<\/li> <li>Ortakl\u0131klardan sa\u011flam gelir ak\u0131\u015flar\u0131<\/li> <\/ul> <p><strong>2030 Vizyonu<\/strong>: 100 $+ potansiyel<\/p> <ul> <li>Birden fazla onaylanm\u0131\u015f terapi<\/li> <li>S\u00fcrd\u00fcr\u00fclebilir k\u00e2rl\u0131l\u0131k sa\u011flanm\u0131\u015f<\/li> <\/ul> <p>Bu projeksiyonlar ba\u015far\u0131l\u0131 klinik sonu\u00e7lar varsay\u0131m\u0131na dayan\u0131r\u2014her biyoteknoloji yat\u0131r\u0131mc\u0131s\u0131n\u0131n kabul etmesi gereken temel risk fakt\u00f6r\u00fc.<\/p> <h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3> <ul> <li><strong>Klinik Ba\u015far\u0131s\u0131zl\u0131k Riski<\/strong>: \u0130la\u00e7 adaylar\u0131n\u0131n yaln\u0131zca yakla\u015f\u0131k %6's\u0131 FDA onay\u0131 al\u0131r<\/li> <li><strong>Nakit Yakma Endi\u015feleri<\/strong>: G\u00fc\u00e7l\u00fc nakit pozisyonuna ra\u011fmen \u00e7eyreklik 17 milyon $ zarar<\/li> <li><strong>Rekabet Bask\u0131s\u0131<\/strong>: Kalabal\u0131k ADC ve obezite pazarlar\u0131<\/li> <li><strong>Reg\u00fclasyon Belirsizli\u011fi<\/strong>: FDA onay s\u00fcre\u00e7leri \u00f6ng\u00f6r\u00fclemez<\/li> <li><strong>Hisse Seyrelme Riski<\/strong>: Gelecekteki fonlama mevcut hissedarlar\u0131 seyreltebilir<\/li> <\/ul> <h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <ul> <li><strong>Sa\u011flam Nakit Yolu<\/strong>: 116,6 milyon $ operasyonlar\u0131 2027'ye kadar finanse eder<\/li> <li><strong>Birden Fazla Kataliz\u00f6r<\/strong>: 2025'te veri a\u00e7\u0131klamas\u0131 beklenen \u00fc\u00e7 klinik program<\/li> <li><strong>FDA H\u0131zland\u0131r\u0131lm\u0131\u015f Onay<\/strong>: CRB-701 rahim a\u011fz\u0131 kanseri i\u00e7in zaten bu tasar\u0131ma sahip<\/li> <li><strong>Piyasa Zamanlamas\u0131<\/strong>: Obezite ve onkoloji sa\u011fl\u0131k sekt\u00f6r\u00fcn\u00fcn en s\u0131cak alanlar\u0131<\/li> <li><strong>Deneyimli Liderlik<\/strong>: CEO Yuval Cohen'in g\u00fc\u00e7l\u00fc sekt\u00f6r ge\u00e7mi\u015fi<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-5'inden fazlas\u0131n\u0131 y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li> <li><strong>Ortalama Maliyetle Al\u0131m Yap\u0131n<\/strong>: Kas\u0131m kazan\u00e7lar\u0131 \u00f6ncesinde pozisyonunuzu kademeli olarak olu\u015fturun<\/li> <li><strong>Zarar Durdur Seviyeleri Belirleyin<\/strong>: Felaket klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131na kar\u015f\u0131 koruma sa\u011flay\u0131n<\/li> <li><strong>Kataliz\u00f6rleri Takip Edin<\/strong>: ESMO 2025 (Ekim) ve 3. \u00e7eyrek kazan\u00e7lar\u0131 (Kas\u0131m) i\u00e7in takviminizi i\u015faretleyin<\/li> <\/ol> <p><strong>Esprili deneyimli tavsiye<\/strong>: \"CRBP ticareti yapmak t\u0131bbi drama izlemek gibidir\u2014%99 s\u0131k\u0131c\u0131 laboratuvar \u00e7al\u0131\u015fmas\u0131, %1 her \u015feyi belirleyen kalp durduran anlar. Duygusal defibrilat\u00f6r\u00fcn\u00fcz\u00fc unutmay\u0131n!\"<\/p> <h2>\u2705 Corbus Pharmaceuticals Holdings, Inc. (CRBP) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir Ticaret Platformu Se\u00e7in<\/td><td>NASDAQ eri\u015fimi ve makul \u00fccretler sundu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td><td>Kaybetmeyi g\u00f6ze alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>\"CRBP\" Aray\u0131n<\/td><td>Corbus Pharmaceuticals i\u00e7in do\u011fru sembol\u00fc kullan\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td><td>Volatil hisselerde giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td><\/tr> <tr><td>5<\/td><td>\u0130nceleyin ve Onaylay\u0131n<\/td><td>Emir detaylar\u0131n\u0131 sonland\u0131rmadan \u00f6nce \u00e7ift kontrol edin<\/td><\/tr> <tr><td>6<\/td><td>Fiyat Uyar\u0131lar\u0131 Ayarlay\u0131n<\/td><td>\u00d6nemli destek\/diren\u00e7 seviyelerini takip edin<\/td><\/tr> <tr><td>7<\/td><td>\u00c7\u0131k\u0131\u015f Stratejinizi Planlay\u0131n<\/td><td>K\u00e2r alma ve zarar durdur seviyelerini \u00f6nceden belirleyin<\/td><\/tr> <tr><td>8<\/td><td>Yat\u0131r\u0131m Tezinizi Belgeleyin<\/td><td>Duygusal kararlar\u0131 \u00f6nlemek i\u00e7in neden yat\u0131r\u0131m yapt\u0131\u011f\u0131n\u0131z\u0131 yaz\u0131n<\/td><\/tr> <tr><td>9<\/td><td>\u015eirket Haberlerini Takip Edin<\/td><td>CRBP klinik g\u00fcncellemeleri i\u00e7in Google uyar\u0131lar\u0131 kurun<\/td><\/tr> <tr><td>10<\/td><td>\u00c7eyreklik \u0130nceleme Yap\u0131n<\/td><td>Her kazan\u00e7 raporundan sonra yat\u0131r\u0131m\u0131n\u0131z\u0131 yeniden de\u011ferlendirin<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Pocket Option Biyoteknoloji Yat\u0131r\u0131m\u0131 \u0130\u00e7in Neden \u00dcst\u00fcn?<\/h2> <p>Pocket Option, CRBP gibi volatil biyoteknoloji hisseleri i\u00e7in m\u00fckemmel \u00f6zelliklerle biyoteknoloji hisse ticaretinde devrim yarat\u0131yor:<\/p> <ul> <li><strong>Minimum Yat\u0131r\u0131m Sadece 5 $<\/strong> - Ger\u00e7ek para ile stratejileri \u00f6nemli risk olmadan test edin<\/li> <li><strong>Y\u0131ld\u0131r\u0131m H\u0131z\u0131nda Emir Ger\u00e7ekle\u015ftirme<\/strong> - Biyoteknoloji haberlerine dayal\u0131 hareketleri yakalamak i\u00e7in kritik<\/li> <li><strong>Geli\u015fmi\u015f Grafik Ara\u00e7lar\u0131<\/strong> - Klinik kataliz\u00f6rler etraf\u0131nda giri\u015f zamanlamas\u0131 i\u00e7in teknik analiz<\/li> <li><strong>K\u00fcresel Piyasa Eri\u015fimi<\/strong> - D\u00fcnyan\u0131n her yerinden ABD biyoteknoloji hisseleri ticareti yap\u0131n<\/li> <li><strong>E\u011fitim Kaynaklar\u0131<\/strong> - <a href=\"\/blog\">Pocket Option blogu<\/a> arac\u0131l\u0131\u011f\u0131yla biyoteknoloji yat\u0131r\u0131m\u0131 \u00f6\u011frenin<\/li> <\/ul> <p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, karma\u015f\u0131k biyoteknoloji analizini yeni ba\u015flayanlar i\u00e7in eri\u015filebilir k\u0131larken deneyimli t\u00fcccarlara geli\u015fmi\u015f ara\u00e7lar sunar.<\/p> <h2>\ud83c\udf0d 2025'te Corbus: Onkoloji Yenili\u011fi Metabolik Bilimle Bulu\u015fuyor<\/h2> <p>Corbus Pharmaceuticals, \u00fc\u00e7 \u00e7\u0131\u011f\u0131r a\u00e7an klinik programla t\u0131bbi yenili\u011fin \u00f6n saflar\u0131nda yer al\u0131yor:<\/p> <ul> <li><strong>CRB-701<\/strong> - Solid t\u00fcm\u00f6rlerde umut verici erken sonu\u00e7lar g\u00f6steren Nectin-4 hedefli antikor-ila\u00e7 konjugat\u0131. <a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/08\/05\/3127283\/0\/en\/Corbus-Pharmaceuticals-Reports-Second-Quarter-2025-Financial-Results-and-Provides-a-Corporate-Update.html\">FDA H\u0131zland\u0131r\u0131lm\u0131\u015f Onay tasar\u0131m\u0131<\/a> rahim a\u011fz\u0131 kanseri tedavisi i\u00e7in potansiyelini vurguluyor.<\/li> <li><strong>CRB-913<\/strong> - \u00d6nceki CB1 inhibit\u00f6rlerini ba\u015far\u0131s\u0131z k\u0131lan n\u00f6rolojik yan etkilerden ka\u00e7\u0131nan yeni nesil obezite tedavisi. Ba\u015flat\u0131lan Faz 1 \u00e7al\u0131\u015fmas\u0131, 100 milyar $+ obezite pazar\u0131na eri\u015fim sa\u011flayabilir.<\/li> <li><strong>CRB-601<\/strong> - Birden fazla solid t\u00fcm\u00f6r tipini hedefleyen anti-integrin tedavisi, \u015firketin \u00fc\u00e7\u00fcnc\u00fc b\u00fcy\u00fck klinik f\u0131rsat\u0131n\u0131 temsil ediyor.<\/li> <\/ul> <p><strong>\u0130lgin\u00e7 Ger\u00e7ek<\/strong>: 2025 y\u0131l\u0131nda Corbus, ayn\u0131 anda \u00fc\u00e7 farkl\u0131 klinik program\u0131 ilerleten ve 2027'ye kadar nakit yolu sa\u011flayan birka\u00e7 biyoteknoloji \u015firketinden biri oldu\u2014nadir g\u00f6r\u00fclen sermaye verimlili\u011fi ba\u015far\u0131s\u0131 biyofarma sekt\u00f6r\u00fcnde dikkat \u00e7ekici bir ba\u015far\u0131d\u0131r.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 CRBP Hisse Analizi: Mevcut Fiyat ve Piyasa Konumu<\/h2>\n<p>25 A\u011fustos 2025 itibar\u0131yla Corbus Pharmaceuticals Holdings, Inc. (CRBP) <strong>9,22 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor\u2014bu volatil biyoteknoloji hissesi i\u00e7in kritik bir d\u00f6neme\u00e7. Hisse senedi bir ini\u015f \u00e7\u0131k\u0131\u015f treni ya\u015fad\u0131, ancak mevcut seviyeler bilgili yat\u0131r\u0131mc\u0131lar i\u00e7in ilgi \u00e7ekici f\u0131rsatlar sunuyor.<\/p>\n<p><strong>Takviminize not edin: Kas\u0131m 2025 kesinlikle kritik!<\/strong> CRBP&#8217;nin bir sonraki kazan\u00e7 raporunu a\u00e7\u0131klamas\u0131 bekleniyor ve tarihsel olarak bu anlar biyoteknoloji hisselerinde b\u00fcy\u00fck fiyat hareketleri yarat\u0131yor.<\/p>\n<h3>Klinik Deneme Sonu\u00e7lar\u0131 CRBP Hissesini Nas\u0131l Hareket Ettirir<\/h3>\n<p>Biyoteknoloji sekt\u00f6r\u00fc klinik deneme sonu\u00e7lar\u0131na ba\u011fl\u0131d\u0131r. CRBP i\u00e7in desen a\u00e7\u0131k: olumlu veriler patlay\u0131c\u0131 y\u00fckseli\u015f yarat\u0131rken, hayal k\u0131r\u0131kl\u0131\u011f\u0131 yaratan sonu\u00e7lar \u015fiddetli sat\u0131\u015flara yol a\u00e7ar. \u015eirketin son finansal istikrar\u0131\u2014<a href=\"https:\/\/ir.corbuspharma.com\/news-events\/press-releases\/detail\/447\/corbus-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\">2025 2. \u00e7eyrek itibar\u0131yla 116,6 milyon $ nakit pozisyonu<\/a>\u2014kritik veri a\u00e7\u0131klamalar\u0131nda \u00f6nemli bir destek sa\u011fl\u0131yor.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd04 6 Ayl\u0131k Fiyat Yolculu\u011fu: Umutsuzluktan Umuda<\/h2>\n<p>CRBP son alt\u0131 ayda a\u015f\u0131r\u0131 volatilite ya\u015fad\u0131 ve biyoteknoloji yat\u0131r\u0131m\u0131n\u0131n y\u00fcksek risk, y\u00fcksek \u00f6d\u00fcl do\u011fas\u0131n\u0131 m\u00fckemmel \u015fekilde g\u00f6sterdi:<\/p>\n<table>\n<thead>\n<tr>\n<th>Ay<\/th>\n<th>Fiyat Aral\u0131\u011f\u0131<\/th>\n<th>Ana Kataliz\u00f6r<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Mart 2025<\/td>\n<td>4,50 $-6,20 $<\/td>\n<td>Piyasa belirsizli\u011fi, sekt\u00f6r rotasyonu<\/td>\n<\/tr>\n<tr>\n<td>Nisan 2025<\/td>\n<td>5,80 $-7,40 $<\/td>\n<td>Erken CRB-701 veri iyimserli\u011fi<\/td>\n<\/tr>\n<tr>\n<td>May\u0131s 2025<\/td>\n<td>6,90 $-8,70 $<\/td>\n<td>RBC Capital Markets sunum heyecan\u0131<\/td>\n<\/tr>\n<tr>\n<td>Haziran 2025<\/td>\n<td>7,20 $-9,10 $<\/td>\n<td>CRB-913 Faz 1 ba\u015flat\u0131lmas\u0131<\/td>\n<\/tr>\n<tr>\n<td>Temmuz 2025<\/td>\n<td>8,50 $-10,80 $<\/td>\n<td>2. \u00e7eyrek kazan\u00e7lar\u0131 beklentilerin \u00fczerinde<\/td>\n<\/tr>\n<tr>\n<td>A\u011fustos 2025<\/td>\n<td>8,80 $-11,20 $<\/td>\n<td>ESMO 2025 beklentisi art\u0131yor<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Genel Trend<\/strong>: Mart diplerinden %104 toparlanma, ba\u015far\u0131l\u0131 biyoteknoloji d\u00f6n\u00fc\u015flerinde inan\u0131lmaz toparlanma potansiyelini g\u00f6steriyor.<\/p>\n<p>Hissenin \u015fiddetli dalgalanmalar\u0131 klinik deneme sonu\u00e7lar\u0131n\u0131n ikili do\u011fas\u0131n\u0131 yans\u0131t\u0131yor\u2014her veri a\u00e7\u0131klamas\u0131 \u015firketi yapabilecek veya bozabilecek bir olayd\u0131r.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut klinik ilerleme ve analist projeksiyonlar\u0131na dayanarak, gelecekte neler olabilece\u011fine dair \u00f6ng\u00f6r\u00fcler:<\/p>\n<p><strong>2025 Y\u0131l Sonu<\/strong>: 18-25 $ aral\u0131\u011f\u0131 (%95-171 y\u00fckseli\u015f)<\/p>\n<ul>\n<li>Kataliz\u00f6rler: ESMO veri a\u00e7\u0131klamas\u0131, CRB-913 Faz 1 tamamlanmas\u0131<\/li>\n<li><strong>Karar<\/strong>: Risk tolerans\u0131 y\u00fcksek yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00dc\u00c7L\u00dc ALIM<\/li>\n<\/ul>\n<p><strong>2026 Projeksiyonu<\/strong>: 30-45 $ aral\u0131\u011f\u0131<\/p>\n<ul>\n<li>FDA H\u0131zland\u0131r\u0131lm\u0131\u015f Onay tasar\u0131lar\u0131 geni\u015fleyebilir<\/li>\n<li>Ortakl\u0131k f\u0131rsatlar\u0131 \u015fekilleniyor<\/li>\n<\/ul>\n<p><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 60-85 $ aral\u0131\u011f\u0131<\/p>\n<ul>\n<li>Muhtemel ilk ticari \u00fcr\u00fcn lansmanlar\u0131<\/li>\n<li>Ortakl\u0131klardan sa\u011flam gelir ak\u0131\u015flar\u0131<\/li>\n<\/ul>\n<p><strong>2030 Vizyonu<\/strong>: 100 $+ potansiyel<\/p>\n<ul>\n<li>Birden fazla onaylanm\u0131\u015f terapi<\/li>\n<li>S\u00fcrd\u00fcr\u00fclebilir k\u00e2rl\u0131l\u0131k sa\u011flanm\u0131\u015f<\/li>\n<\/ul>\n<p>Bu projeksiyonlar ba\u015far\u0131l\u0131 klinik sonu\u00e7lar varsay\u0131m\u0131na dayan\u0131r\u2014her biyoteknoloji yat\u0131r\u0131mc\u0131s\u0131n\u0131n kabul etmesi gereken temel risk fakt\u00f6r\u00fc.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3>\n<ul>\n<li><strong>Klinik Ba\u015far\u0131s\u0131zl\u0131k Riski<\/strong>: \u0130la\u00e7 adaylar\u0131n\u0131n yaln\u0131zca yakla\u015f\u0131k %6&#8217;s\u0131 FDA onay\u0131 al\u0131r<\/li>\n<li><strong>Nakit Yakma Endi\u015feleri<\/strong>: G\u00fc\u00e7l\u00fc nakit pozisyonuna ra\u011fmen \u00e7eyreklik 17 milyon $ zarar<\/li>\n<li><strong>Rekabet Bask\u0131s\u0131<\/strong>: Kalabal\u0131k ADC ve obezite pazarlar\u0131<\/li>\n<li><strong>Reg\u00fclasyon Belirsizli\u011fi<\/strong>: FDA onay s\u00fcre\u00e7leri \u00f6ng\u00f6r\u00fclemez<\/li>\n<li><strong>Hisse Seyrelme Riski<\/strong>: Gelecekteki fonlama mevcut hissedarlar\u0131 seyreltebilir<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<ul>\n<li><strong>Sa\u011flam Nakit Yolu<\/strong>: 116,6 milyon $ operasyonlar\u0131 2027&#8217;ye kadar finanse eder<\/li>\n<li><strong>Birden Fazla Kataliz\u00f6r<\/strong>: 2025&#8217;te veri a\u00e7\u0131klamas\u0131 beklenen \u00fc\u00e7 klinik program<\/li>\n<li><strong>FDA H\u0131zland\u0131r\u0131lm\u0131\u015f Onay<\/strong>: CRB-701 rahim a\u011fz\u0131 kanseri i\u00e7in zaten bu tasar\u0131ma sahip<\/li>\n<li><strong>Piyasa Zamanlamas\u0131<\/strong>: Obezite ve onkoloji sa\u011fl\u0131k sekt\u00f6r\u00fcn\u00fcn en s\u0131cak alanlar\u0131<\/li>\n<li><strong>Deneyimli Liderlik<\/strong>: CEO Yuval Cohen&#8217;in g\u00fc\u00e7l\u00fc sekt\u00f6r ge\u00e7mi\u015fi<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-5&#8217;inden fazlas\u0131n\u0131 y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li>\n<li><strong>Ortalama Maliyetle Al\u0131m Yap\u0131n<\/strong>: Kas\u0131m kazan\u00e7lar\u0131 \u00f6ncesinde pozisyonunuzu kademeli olarak olu\u015fturun<\/li>\n<li><strong>Zarar Durdur Seviyeleri Belirleyin<\/strong>: Felaket klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131na kar\u015f\u0131 koruma sa\u011flay\u0131n<\/li>\n<li><strong>Kataliz\u00f6rleri Takip Edin<\/strong>: ESMO 2025 (Ekim) ve 3. \u00e7eyrek kazan\u00e7lar\u0131 (Kas\u0131m) i\u00e7in takviminizi i\u015faretleyin<\/li>\n<\/ol>\n<p><strong>Esprili deneyimli tavsiye<\/strong>: &#8220;CRBP ticareti yapmak t\u0131bbi drama izlemek gibidir\u2014%99 s\u0131k\u0131c\u0131 laboratuvar \u00e7al\u0131\u015fmas\u0131, %1 her \u015feyi belirleyen kalp durduran anlar. Duygusal defibrilat\u00f6r\u00fcn\u00fcz\u00fc unutmay\u0131n!&#8221;<\/p>\n<h2>\u2705 Corbus Pharmaceuticals Holdings, Inc. (CRBP) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir Ticaret Platformu Se\u00e7in<\/td>\n<td>NASDAQ eri\u015fimi ve makul \u00fccretler sundu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td>\n<td>Kaybetmeyi g\u00f6ze alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;CRBP&#8221; Aray\u0131n<\/td>\n<td>Corbus Pharmaceuticals i\u00e7in do\u011fru sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td>\n<td>Volatil hisselerde giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130nceleyin ve Onaylay\u0131n<\/td>\n<td>Emir detaylar\u0131n\u0131 sonland\u0131rmadan \u00f6nce \u00e7ift kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Fiyat Uyar\u0131lar\u0131 Ayarlay\u0131n<\/td>\n<td>\u00d6nemli destek\/diren\u00e7 seviyelerini takip edin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>\u00c7\u0131k\u0131\u015f Stratejinizi Planlay\u0131n<\/td>\n<td>K\u00e2r alma ve zarar durdur seviyelerini \u00f6nceden belirleyin<\/td>\n<\/tr>\n<tr>\n<td>8<\/td>\n<td>Yat\u0131r\u0131m Tezinizi Belgeleyin<\/td>\n<td>Duygusal kararlar\u0131 \u00f6nlemek i\u00e7in neden yat\u0131r\u0131m yapt\u0131\u011f\u0131n\u0131z\u0131 yaz\u0131n<\/td>\n<\/tr>\n<tr>\n<td>9<\/td>\n<td>\u015eirket Haberlerini Takip Edin<\/td>\n<td>CRBP klinik g\u00fcncellemeleri i\u00e7in Google uyar\u0131lar\u0131 kurun<\/td>\n<\/tr>\n<tr>\n<td>10<\/td>\n<td>\u00c7eyreklik \u0130nceleme Yap\u0131n<\/td>\n<td>Her kazan\u00e7 raporundan sonra yat\u0131r\u0131m\u0131n\u0131z\u0131 yeniden de\u011ferlendirin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option Biyoteknoloji Yat\u0131r\u0131m\u0131 \u0130\u00e7in Neden \u00dcst\u00fcn?<\/h2>\n<p>Pocket Option, CRBP gibi volatil biyoteknoloji hisseleri i\u00e7in m\u00fckemmel \u00f6zelliklerle biyoteknoloji hisse ticaretinde devrim yarat\u0131yor:<\/p>\n<ul>\n<li><strong>Minimum Yat\u0131r\u0131m Sadece 5 $<\/strong> &#8211; Ger\u00e7ek para ile stratejileri \u00f6nemli risk olmadan test edin<\/li>\n<li><strong>Y\u0131ld\u0131r\u0131m H\u0131z\u0131nda Emir Ger\u00e7ekle\u015ftirme<\/strong> &#8211; Biyoteknoloji haberlerine dayal\u0131 hareketleri yakalamak i\u00e7in kritik<\/li>\n<li><strong>Geli\u015fmi\u015f Grafik Ara\u00e7lar\u0131<\/strong> &#8211; Klinik kataliz\u00f6rler etraf\u0131nda giri\u015f zamanlamas\u0131 i\u00e7in teknik analiz<\/li>\n<li><strong>K\u00fcresel Piyasa Eri\u015fimi<\/strong> &#8211; D\u00fcnyan\u0131n her yerinden ABD biyoteknoloji hisseleri ticareti yap\u0131n<\/li>\n<li><strong>E\u011fitim Kaynaklar\u0131<\/strong> &#8211; <a href=\"\/blog\">Pocket Option blogu<\/a> arac\u0131l\u0131\u011f\u0131yla biyoteknoloji yat\u0131r\u0131m\u0131 \u00f6\u011frenin<\/li>\n<\/ul>\n<p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, karma\u015f\u0131k biyoteknoloji analizini yeni ba\u015flayanlar i\u00e7in eri\u015filebilir k\u0131larken deneyimli t\u00fcccarlara geli\u015fmi\u015f ara\u00e7lar sunar.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te Corbus: Onkoloji Yenili\u011fi Metabolik Bilimle Bulu\u015fuyor<\/h2>\n<p>Corbus Pharmaceuticals, \u00fc\u00e7 \u00e7\u0131\u011f\u0131r a\u00e7an klinik programla t\u0131bbi yenili\u011fin \u00f6n saflar\u0131nda yer al\u0131yor:<\/p>\n<ul>\n<li><strong>CRB-701<\/strong> &#8211; Solid t\u00fcm\u00f6rlerde umut verici erken sonu\u00e7lar g\u00f6steren Nectin-4 hedefli antikor-ila\u00e7 konjugat\u0131. <a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/08\/05\/3127283\/0\/en\/Corbus-Pharmaceuticals-Reports-Second-Quarter-2025-Financial-Results-and-Provides-a-Corporate-Update.html\">FDA H\u0131zland\u0131r\u0131lm\u0131\u015f Onay tasar\u0131m\u0131<\/a> rahim a\u011fz\u0131 kanseri tedavisi i\u00e7in potansiyelini vurguluyor.<\/li>\n<li><strong>CRB-913<\/strong> &#8211; \u00d6nceki CB1 inhibit\u00f6rlerini ba\u015far\u0131s\u0131z k\u0131lan n\u00f6rolojik yan etkilerden ka\u00e7\u0131nan yeni nesil obezite tedavisi. Ba\u015flat\u0131lan Faz 1 \u00e7al\u0131\u015fmas\u0131, 100 milyar $+ obezite pazar\u0131na eri\u015fim sa\u011flayabilir.<\/li>\n<li><strong>CRB-601<\/strong> &#8211; Birden fazla solid t\u00fcm\u00f6r tipini hedefleyen anti-integrin tedavisi, \u015firketin \u00fc\u00e7\u00fcnc\u00fc b\u00fcy\u00fck klinik f\u0131rsat\u0131n\u0131 temsil ediyor.<\/li>\n<\/ul>\n<p><strong>\u0130lgin\u00e7 Ger\u00e7ek<\/strong>: 2025 y\u0131l\u0131nda Corbus, ayn\u0131 anda \u00fc\u00e7 farkl\u0131 klinik program\u0131 ilerleten ve 2027&#8217;ye kadar nakit yolu sa\u011flayan birka\u00e7 biyoteknoloji \u015firketinden biri oldu\u2014nadir g\u00f6r\u00fclen sermaye verimlili\u011fi ba\u015far\u0131s\u0131 biyofarma sekt\u00f6r\u00fcnde dikkat \u00e7ekici bir ba\u015far\u0131d\u0131r.<\/p>\n"},"faq":[{"question":"Corbus Pharmaceuticals hisseleri nas\u0131l al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \"CRBP\" sembol\u00fcn\u00fc aray\u0131n, emir t\u00fcr\u00fcn\u00fc se\u00e7in, detaylar\u0131 kontrol edip onaylay\u0131n ve fiyat uyar\u0131lar\u0131 ile \u00e7\u0131k\u0131\u015f stratejinizi planlay\u0131n."},{"question":"CRBP hisselerinin fiyat\u0131n\u0131 etkileyen ana fakt\u00f6rler nelerdir?","answer":"Klinik deneme sonu\u00e7lar\u0131, finansal raporlar, FDA onaylar\u0131 ve piyasa kataliz\u00f6rleri CRBP hisselerinin fiyat\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde etkiler."},{"question":"Corbus Pharmaceuticals'\u0131n 2025 sonras\u0131 fiyat tahmini nedir?","answer":"2025 sonunda 18-25 $ aral\u0131\u011f\u0131nda, 2026'da 30-45 $, 2028'de 60-85 $ ve 2030'da 100 $+ potansiyel fiyat \u00f6ng\u00f6r\u00fclmektedir."},{"question":"Biyoteknoloji hisselerine yat\u0131r\u0131m yaparken hangi riskler vard\u0131r?","answer":"Klinik ba\u015far\u0131s\u0131zl\u0131k, nakit yakma, rekabet bask\u0131s\u0131, reg\u00fclasyon belirsizli\u011fi ve hisse seyrelme riski ba\u015fl\u0131ca risklerdir."},{"question":"Yeni ba\u015flayanlar CRBP hisseleri i\u00e7in nas\u0131l bir strateji izlemeli?","answer":"Portf\u00f6y\u00fcn k\u00fc\u00e7\u00fck bir k\u0131sm\u0131yla ba\u015flay\u0131p, kademeli al\u0131m yapmal\u0131, zarar durdur seviyeleri belirlemeli ve \u00f6nemli kataliz\u00f6rleri takip etmelidir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Corbus Pharmaceuticals hisseleri nas\u0131l al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \"CRBP\" sembol\u00fcn\u00fc aray\u0131n, emir t\u00fcr\u00fcn\u00fc se\u00e7in, detaylar\u0131 kontrol edip onaylay\u0131n ve fiyat uyar\u0131lar\u0131 ile \u00e7\u0131k\u0131\u015f stratejinizi planlay\u0131n."},{"question":"CRBP hisselerinin fiyat\u0131n\u0131 etkileyen ana fakt\u00f6rler nelerdir?","answer":"Klinik deneme sonu\u00e7lar\u0131, finansal raporlar, FDA onaylar\u0131 ve piyasa kataliz\u00f6rleri CRBP hisselerinin fiyat\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde etkiler."},{"question":"Corbus Pharmaceuticals'\u0131n 2025 sonras\u0131 fiyat tahmini nedir?","answer":"2025 sonunda 18-25 $ aral\u0131\u011f\u0131nda, 2026'da 30-45 $, 2028'de 60-85 $ ve 2030'da 100 $+ potansiyel fiyat \u00f6ng\u00f6r\u00fclmektedir."},{"question":"Biyoteknoloji hisselerine yat\u0131r\u0131m yaparken hangi riskler vard\u0131r?","answer":"Klinik ba\u015far\u0131s\u0131zl\u0131k, nakit yakma, rekabet bask\u0131s\u0131, reg\u00fclasyon belirsizli\u011fi ve hisse seyrelme riski ba\u015fl\u0131ca risklerdir."},{"question":"Yeni ba\u015flayanlar CRBP hisseleri i\u00e7in nas\u0131l bir strateji izlemeli?","answer":"Portf\u00f6y\u00fcn k\u00fc\u00e7\u00fck bir k\u0131sm\u0131yla ba\u015flay\u0131p, kademeli al\u0131m yapmal\u0131, zarar durdur seviyeleri belirlemeli ve \u00f6nemli kataliz\u00f6rleri takip etmelidir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Corbus Pharmaceuticals Holdings, Inc. (CRBP) Hisseleri Nas\u0131l Al\u0131n\u0131r - Corbus Pharmaceuticals Holdings, Inc. (CRBP) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Corbus Pharmaceuticals Holdings, Inc. (CRBP) Hisseleri Nas\u0131l Al\u0131n\u0131r - Corbus Pharmaceuticals Holdings, Inc. (CRBP) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T20:21:20+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Corbus Pharmaceuticals Holdings, Inc. (CRBP) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Corbus Pharmaceuticals Holdings, Inc. (CRBP) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-25T20:21:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/\"},\"wordCount\":23,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/\",\"name\":\"Corbus Pharmaceuticals Holdings, Inc. (CRBP) Hisseleri Nas\u0131l Al\u0131n\u0131r - Corbus Pharmaceuticals Holdings, Inc. (CRBP) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp\",\"datePublished\":\"2025-08-25T20:21:20+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Corbus Pharmaceuticals Holdings, Inc. (CRBP) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Corbus Pharmaceuticals Holdings, Inc. (CRBP) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Corbus Pharmaceuticals Holdings, Inc. (CRBP) Hisseleri Nas\u0131l Al\u0131n\u0131r - Corbus Pharmaceuticals Holdings, Inc. (CRBP) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/","og_locale":"tr_TR","og_type":"article","og_title":"Corbus Pharmaceuticals Holdings, Inc. (CRBP) Hisseleri Nas\u0131l Al\u0131n\u0131r - Corbus Pharmaceuticals Holdings, Inc. (CRBP) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T20:21:20+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Corbus Pharmaceuticals Holdings, Inc. (CRBP) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Corbus Pharmaceuticals Holdings, Inc. (CRBP) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-25T20:21:20+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/"},"wordCount":23,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/","name":"Corbus Pharmaceuticals Holdings, Inc. (CRBP) Hisseleri Nas\u0131l Al\u0131n\u0131r - Corbus Pharmaceuticals Holdings, Inc. (CRBP) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp","datePublished":"2025-08-25T20:21:20+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Corbus Pharmaceuticals Holdings, Inc. (CRBP) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Corbus Pharmaceuticals Holdings, Inc. (CRBP) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":351067,"slug":"how-to-buy-corbus-pharmaceuticals-holdings","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Corbus Pharmaceuticals Holdings, Inc. (CRBP) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Corbus Pharmaceuticals Holdings, Inc. (CRBP)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/"},"pt_AA":{"locale":"pt_AA","id":351063,"slug":"how-to-buy-corbus-pharmaceuticals-holdings","post_title":"Como comprar a\u00e7\u00f5es da Corbus Pharmaceuticals Holdings, Inc. (CRBP) - Investimento em a\u00e7\u00f5es da Corbus Pharmaceuticals Holdings, Inc. (CRBP)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-corbus-pharmaceuticals-holdings\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/351066","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=351066"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/351066\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334009"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=351066"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=351066"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=351066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}